----item----
version: 1
id: {F99F55DA-B349-4F41-834A-9F406F8AD2FC}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/06/30/Dyax shares score on HAE drug breakthrough status
parent: {E67CB7D0-70DE-425B-8565-3BEAD05ACFC4}
name: Dyax shares score on HAE drug breakthrough status
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: ac69097b-3ace-46b2-a3f3-346d904420f7

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 51

Dyax shares score on HAE drug 'breakthrough' status
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 49

Dyax shares score on HAE drug breakthrough status
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 3013

<p>Shares of Dyax jumped about 5% in morning trading on 7 July on word the FDA had granted breakthrough therapy designation (BTD) &ndash; a mechanism intended to help expedite the regulatory process for medicines aimed at treating serious conditions &ndash; for the company's investigational hereditary angioedema (HAE) drug of DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein (pKal).</p><p>Uncontrolled pKal activity leads to excessive generation of bradykinin, a vasodilator thought to be responsible for the localized swelling, inflammation and pain characteristically associated with HAE, a rare acute inflammatory condition that affect up to 1 in 50,000 individuals.</p><p>HAE is caused by low or dysfunctional levels of C1 esterase inhibitor, a naturally occurring molecule that inhibits pKal, a key mediator of inflammation, and other serine proteases in the blood.</p><p>The disease is characterized by episodes of severe, often painful swelling affecting the extremities, gastrointestinal tract, genitalia and the larynx.</p><p>Dyax is developing DX-2930 as a subcutaneous injection to prevent attacks associated with HAE.</p><p>Winning the BTD status for the drug, said Dr Burt Adelman, chief medical officer at Dyax, is a "key milestone" for DX-2930.</p><p>To <a href="http://www.scripintelligence.com/home/US-Capitol-Capsule-Breakthrough-fees-FDA-urges-self-control-on-requests-358065" target="_new">gain the BTD status</a>, which was <a href="http://www.scripintelligence.com/home/All-too-easy-Obama-signs-US-FDA-user-fee-bill-without-fanfare-332602" target="_new">created</a><i>the Food and Drug Administration Safety and Innovation Act</i>, a drug must be intended to treat a serious condition and have preliminary clinical evidence that indicates the medicine may demonstrate substantial improvement on at least one clinically significant endpoint over available therapies.</p><p>As of 26 June &ndash; the most recent date for which data are available &ndash; the FDA's Center for Drug Evaluation and Research had granted at least 79 of the 263 requests for the breakthrough designation it has received since July 2012, with regulators denying at least 132.</p><p>As of 30 June, the FDA's Center for Biologics Evaluation and Research had granted at least 14 of the 52 requests it has received for breakthrough status, denying at least 36.</p><p>The BTD for DX-2930 was supported by the interim results of Dyax's Phase Ib trial, which met all objectives assessing safety, tolerability and pharmacokinetics of multiple subcutaneous administrations of the experimental drug, the firm reported. </p><p>In a pre-specified proof-of-concept efficacy analysis, DX-2930 demonstrated statistically significant reductions in attack rate compared to placebo, the company said. </p><p>Dyax already has one HAE drug on the US market &ndash; Kalbitor (ecallantide), which is approved to treat acute attacks of the disease in patients 12 years or older. </p><p><p><p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 413

<p>Shares of Dyax jumped about 5% in morning trading on 7 July on word the FDA had granted breakthrough therapy designation (BTD) &ndash; a mechanism intended to help expedite the regulatory process for medicines aimed at treating serious conditions &ndash; for the company's investigational hereditary angioedema (HAE) drug of DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein (pKal).</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 49

Dyax shares score on HAE drug breakthrough status
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150630T235619
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150630T235619
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150630T235619
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029170
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 51

Dyax shares score on HAE drug 'breakthrough' status
----field----
field: {53288D3D-66D7-4ACE-B3E4-D7D02B1F3672}
name: Referenced Companies
key: referenced companies
content-length: 9

198800552
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

Headline News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

359201
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042418Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

ac69097b-3ace-46b2-a3f3-346d904420f7
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042418Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
